Last update: June 29, 2020
Increased level of risk
New scientific evidences have driven the Apilam staff to update the level of risk associated to this product.
Former level of risk, which was Low Risk, is now set to High Risk.
Level of risk reviewed on June 29, 2020
Poorly safe. Evaluate carefully.
Use safer alternative or interrupt breastfeeding 3 to 7 T ½ (elimination half-lives).
Read the Comment.
Long-acting bronchodilator such as salmeterol that, when inhaled, does not reach plasma in significant quantities.
Since the last update we have not found any published data on its excretion in breast milk.
Its pharmacokinetic data: low molecular weight, low protein binding and long half-life (Yang 2015) makes transfer to milk possible in amounts that could be significant.
Clenbuterol does not alter prolactin levels (Laakmann 1990).
Due to its long half-life, its potential toxicity and illegal uses in veterinary medicine and sports (Woolum 2020) it is not commercialized in several countries. and safer known alternatives are preferred, especially during the neonatal period and in case of prematurity.
Inhaled bronchodilator drugs are preferred because of a lower secretion into breast milk.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine from United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM